Fushimi, Japan

Tomoaki Hamakawa

This inventor holds 1 USPTO granted patent. Top assignee: Nippon Shinyaku Company, Ltd.. Active years: 1989.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Tomoaki Hamakawa. Retrieved from https://idiyas.com/inventor/tomoaki-hamakawa

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


% Patents Active = 100.0

Average Co-Inventor Count = 3.0

ph-index = 1

Forward Citations = 3(Granted Patents)


Company Filing History:


Years Active: 1989

Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovations of Tomoaki Hamakawa

Introduction

Tomoaki Hamakawa is a notable inventor based in Fushimi, Japan. He has made significant contributions to the field of pharmaceuticals, particularly in the formulation of medications. His work has had a profound impact on the treatment of cardiovascular conditions.

Latest Patents

Hamakawa holds a patent for "Nifedipine compositions and the production thereof." This patent involves the formulation of Nifedipine into a reactally administrable composition for administration to humans and animals. The primary purpose of this formulation is to effect coronary dilation and provide a hypotensive effect. He has 1 patent to his name.

Career Highlights

Hamakawa is associated with Nippon Shinyaku Company, Ltd., where he has been instrumental in developing innovative pharmaceutical solutions. His expertise in drug formulation has contributed to advancements in medical treatments.

Collaborations

Throughout his career, Hamakawa has worked alongside talented colleagues, including Koichi Ushimaru and Tomio Koga. Their collaborative efforts have furthered research and development in the pharmaceutical industry.

Conclusion

Tomoaki Hamakawa's contributions to the field of pharmaceuticals, particularly through his patent on Nifedipine compositions, highlight his role as an influential inventor. His work continues to benefit the medical community and improve patient outcomes.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…